Amgen positions MariTide as potential ‘best monthly’ obesity drug
BioSpace
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or mor
pharminent
May 1, 2026 (Last updated: May 1, 2026)
BioSpace
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could open up monthly or mor
